G1 Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference

Rhea-AI Summary

G1 Therapeutics, Inc. (Nasdaq: GTHX) will have its CEO, Jack Bailey, speak on a Breast and Lung Cancer Panel at the Cowen 43rd Annual Health Care Conference on March 7th, 2023, at 10:30 AM EST. This event is significant for G1, a commercial-stage oncology company focused on developing therapies to improve cancer treatment.

The session will be webcasted and available on the company's Events & Presentations page. G1 Therapeutics is known for its product, COSELA® (trilaciclib), and is actively researching various solid tumors, including breast and lung cancers.

RESEARCH TRIANGLE PARK, N.C., Feb. 28, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that on March 7th, 2023, at 10:30 AM EST, G1’s Chief Executive Officer Jack Bailey will participate in the moderated Breast and Lung Cancer Panel during the Cowen 43^rd Annual Health Care Conference.

The webcast of the event will be accessible on the Events & Presentations page of http://www.g1therapeutics.com.

About G1 Therapeutics
G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of next generation therapies that improve the lives of those affected by cancer, including the Company’s first commercial product, COSELA® (trilaciclib). G1 has a deep clinical pipeline and is executing a development plan evaluating trilaciclib in a variety of solid tumors, including breast, lung, and bladder cancers. G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics.

G1 Therapeutics® and the G1 Therapeutics logo and COSELA® and the COSELA logo are trademarks of G1 Therapeutics, Inc

Contacts:
Will Roberts
Vice President, Investor Relations & Corporate Communications
919-907-1944
wroberts@g1therapeutics.com

FAQ

When will G1 Therapeutics CEO participate in the Cowen 43rd Annual Health Care Conference?

Jack Bailey, CEO of G1 Therapeutics, will participate on March 7th, 2023, at 10:30 AM EST.

How can I access the G1 Therapeutics conference panel discussion?

The event will be webcasted and can be accessed on G1 Therapeutics' Events & Presentations page.

What is G1 Therapeutics' focus in oncology?

G1 Therapeutics focuses on developing and commercializing innovative therapies for cancer treatment, including its product COSELA®.

What cancer types is G1 Therapeutics targeting with trilaciclib?

G1 Therapeutics is evaluating trilaciclib for various solid tumors, specifically breast, lung, and bladder cancers.

What is the ticker symbol for G1 Therapeutics?

The ticker symbol for G1 Therapeutics on NASDAQ is GTHX.